Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by Boomskidon Aug 21, 2023 5:55pm
41 Views
Post# 35598788

RE:RE:Does xB3 Work?

RE:RE:Does xB3 Work?You missed the point, totally, TT.

You gotta be smart and informed if you're going to play smart and informed.

The point of the xB3 questions was and remains to put the CEOs on the public record. Duh! I discussed that for years, but you likely didn't read it, or even more likely, couldn't understand it.

Frankly, I have worried for years about issues with xB3. My questions to the CEOs were to put them on the record. And I did. So did they in every filing, corporate presentation and all their other documents. My efforts were intended to prevent them from using semantics to mislead investors.

And then in 2020 I found a paper that expressed concern about using the LRP-1 as a transport vector across the BBB because of the ubiquity of that receptor in the CNS. The concern was that too much of the payload would be delivered off tartget. I believe that there may be little likelyhood that Daichi Sankyo/AstraZeneca's Enhertu can be delivered to the CNS by xB3 because the cytotoxin with its neighbouring cell toxic delivery would destroy too many healthy cells. 

So don't bother with the "Davenport pumping" nonsense. I was always going after the truth.

Are you being paid to spout this nonsense, TheTruth1234? I mean, attacking me is one thing, but misleading readers about the facts is another.

jd
<< Previous
Bullboard Posts
Next >>